This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.
Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.
Lenalidomide
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
<StructureSection load='4tz4' size='340' side='right' caption='Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide ([[4tz4]])' scene='95/954025/Cv/2'> | <StructureSection load='4tz4' size='340' side='right' caption='Crystal Structure of Human Cereblon in Complex with DDB1 and Lenalidomide ([[4tz4]])' scene='95/954025/Cv/2'> | ||
| - | Lenalidomide, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). See also [https://en.wikipedia.org/wiki/Lenalidomide]. | + | <scene name='95/954025/Cv/4'>Lenalidomide</scene>, sold under the trade name Revlimid among others, is a medication used to treat multiple myeloma, smoldering myeloma, and myelodysplastic syndromes (MDS). See also [https://en.wikipedia.org/wiki/Lenalidomide]. |
On a molecular level, <scene name='95/954025/Cv/3'>lenalidomide has been shown to interact with the ubiquitin E3 ligase cereblon</scene> and target this enzyme to degrade the Ikaros transcription factors IKZF1 and IKZF3. | On a molecular level, <scene name='95/954025/Cv/3'>lenalidomide has been shown to interact with the ubiquitin E3 ligase cereblon</scene> and target this enzyme to degrade the Ikaros transcription factors IKZF1 and IKZF3. | ||
Revision as of 11:27, 27 February 2023
| |||||||||||
